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Poster Session I 61transplant to relapse was 466 days (range 182–729) for the ALL
group, and 2270 days (range 130–4410) for the AML/MDS group.
The primary cause of death was disease recurrence (n 5 11), three
ALL and eight AML/MDS patients. Three patients died of acute
GVHD, 2 from infection, and for one AML/MDS patient a specific
cause of death was not known. These data show that even when re-
lapse after a first HCT occurs, nearly 1/3 of pediatric patients with
acute leukemia may still be salvaged with a second HCT.162
EVALUATION OF A POWERED INTRAOSSEOUS DEVICE FOR BONE MAR-
ROW SAMPLING
Cohen, S.C., Soroka, J.M. Cancer Care Center of South Texas, San An-
tonio, TX.
The importance of bone marrow examination in the evaluation of
leukemia, multiple myeloma, anemia, pancytopenia, and other dis-
orders is well established. The objective for this study was to evalu-
ate the ability of a powered bone marrow aspiration device to
penetrate the intraosseous medullary space of the iliac crest, and
to aspirate bone marrow samples for the ultimate purpose of diag-
nosing disease and monitoring the course of disease and medical
therapy. The device was used to obtain bone marrow samples in ac-
cordance with accepted practice guidelines and device’s directions
for use. Among other data, insertion success, time to insertion,
and complications were recorded. Patient pain levels were rated
from 0 to 10 (105extreme pain). Device operators rated the use
of the device from 0 to 10 (105outstanding). There were 55 patients
in the study from three centers. Successful insertion and aspiration
of bone marrow samples were achieved in 54 of the 55 patients
(98.1%). Mean insertion time was 4.9 6 3.0 seconds; significantly
faster than the 7.3 minutes reported by Kuball et al* (one-sample
t-test, p\ 0.001). There were no complications. The mean inser-
tion pain score was 2.5 6 2.2 and the mean aspiration pain score
was 3.7 6 2.5. On a scale of 0 to 10, the six operators rated the
ease of use of the device at a mean score of 8.36 1.7. Findings sug-
gest that the powered aspiration device is safe and effective for bone
marrow aspirations; and that through the use of powered device,
needle placement time can be reduced—thereby reducing patient
pain.
* Kuball J, Schu¨z J, Gamm H, Weber M. Bone marrow punctures
and pain. Acute Pain 2004;6(1):9–14.163
CLOFARABINE PRE-CONDITIONING PRIOR TO ALLOGENEIC STEM CELL
TRANSPLANTATION IN HIGH RISK ACUTE MYELOID LEUKAEMIA (AML):
A WELL TOLERATED REGIMEN WITH BOTH FULL AND REDUCED TOX-
ICITY SCHEDULES
Richardson, D.S., Hurlock, C., Hill, K., Newman, J., McKeag, N.,
Groves, L., Orchard, K.H. Southampton University Hospitals, South-
ampton, Hampshire, United Kingdom.
The outcome for patients with high-risk AML, particularly those
with leukaemia at the time of allogeneic transplant remains poor
even using full intensity conditioning. A recently published ap-
proach used pre-conditioning chemotherapy prior to the delivery
of a reduced intensity transplant schedule during the period of cyto-
penia. Initial results indicate feasibility and potential for long-term
disease control.
The bi-halogen purine analogue Clofarabine has significant ac-
tivity as a single agent in AML and is well tolerated. These charac-
teristics suggest Clofarabine is an ideal agent to use as pre-
conditioning therapy.
We have treated 5 patients with high-risk, refractory AML using
Clofarabine pre-conditioning to reduce disease burden before full
or reduced intensity allogeneic transplantation. In 4 patients, Clo-
farabine was administered as a single agent (40 mg/m2/day for 5
days) and in one, in combination with Cytarabine. 2 received re-
duced toxicity Busulphan-containing transplant schedules; 3 re-
ceived full intensity, TBI-based conditioning. The indications for
using Clofarabine in these patients, included severe allergy to Cy-
tarabine and heavy prior exposure to anthracycline. All 5 patientshad marrow involvement with AML prior to administration of Clo-
farabine. No unexpected toxicity was encountered and the extended
period of cytopenia compared with a conventional transplant was
manageable in this cohort. One patient who received a reduced in-
tensity regimen, was treated for VOD on the basis of clinical suspi-
cion but liver biopsy showed evidence of grade 3–4 haemosiderosis
only. 2 patients who received TBI suffered grade 3–4 mucositis and
required parenteral nutrition. All patients achieved .98% donor
chimerism at day 130. No patient experienced grade 3–4 acute
GvHD. 4 of 5 patients achieved substantial bulk reduction or erad-
ication of marrow AML infiltration following Clofarabine. The pa-
tient with Clofarabine-refractory disease achieved CR at day 30
following a full intensity transplant but has relapsed at 4 months
post transplant. One patient died in CR at 5 months post transplant
from pneumonitis. 3 patients are currently in CR at 2.5–21 months
follow up. The use of Clofarabine as a pre-conditioning agent prior
to the administration of the transplant conditioning schedule is well
tolerated with both full and reduced intensity protocols. This ap-
proach to allogeneic transplantation shows promise for the therapy
of patients with high risk, refractory AML.164
CLINICAL FEATURES OF ACUTE LEUKEMIA WITH CO-EXPRESSION OF
MYELOID AND LYMPHOID ANTIGENS
Jeong, S.H.1, Lee, H.W.1, Kang, S.Y.1, Cho, S.R.2, Park, J.S.1,
Choi, J.H.1, Kim, H.C.1 1Ajou University School of Medicine, Suwon,
Kyeong-Ki Do, Korea; 2Ajou University School of Medicine, Suwon,
Kyeong-Ki Do, Korea.
Background: Treatment of acute leukemias coexpressing mye-
loid and lymphoid antigens but does not meet the criteria for biphe-
notypic acute leukemia by EGIL is uncertain and its prognosis
unpredictable. We studied clinical outcomes of those acute leuke-
mia with coexpression. Method: Medical charts from 68 patients
diagnosed as coexpressing acute leukemia between Jan. 2000 and
Dec. 2006 in Ajou University Hospital were reviewed retrospec-
tively. 17/52 AML patients and 5/16 ALL patients received Hema-
topoietic stem cell transplantation. Significance was obtained by
two-tailed Student’s t-test and survival analyzed by Kaplan-Meier
method. Results: The median age for all acute leukemia was 42.5
year (15  83). Age, gender, LDH level and cytogenetics were
not different compared to those diagnosed as single lineage acute
leukemia at the same time. Forty eight % (16/33) of ALL and
30% (52/176) of AML patients co-expressed counterpart lineage
markers. CD19 (11%), CD7 (10%), CD22 (8%), CD5 (8%),
CD10 (1%) in AML and CD13 (42%), CD33 (33%), CD14 (3%)
in ALL were co-expressed. The co-expressed AML patients showed
tendency to short survival duration compared with pure AML pa-
tients (18.5 months vs. 24.1 months, p 5 0.069). Co-expressed
AML patients without stem cell transplantation showed shorter sur-
vival than pure AML patients (12.9 months vs. 21 months, p 5
0.014). However in AML who were transplanted, the survival ad-
vantage was abrogated (coexpressed vs pure AML; 30 months vs.
35 months, p 5 0.244). In ALL, survival duration of the co-ex-
pressed patients was not shorter than that of pure ALL (19.4 months
vs. 21 months) regardless of transplantation. Conclusion: AML pa-
tients with co-expression of lymphoid markers should be regarded
as a poor prognostic group and more aggressive treatment such as
transplantation should be considered. Further study on a larger
number of patients should be investigated regarding the appropriate
criteria for BAL and treatment.165
CENTRAL NERVOUS SYSTEM (CNS) INVOLVEMENT AT DIAGNOSIS DOES
NOT ADVERSELY AFFECT THE OUTCOME OF HIGH-DOSE CHEMOTHER-
APY AND TRANSPLANT FOR PATIENTS WITH ACUTE MYELOID LEUKE-
MIA (AML)
Petropoulos, D.1, Giralt, S.A.2, Andersson, B.S.2, Chan, K.W.3,
Rondon, G.2, Popat, U.R.2, Hosing, C.2, Alousi, A.M.2,
Champlin, R.E.2, de Lima, M.J.2 1MD Anderson Cancer Center,
